Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025
Alpha Cognition (NASDAQ: ACOG) reported accelerating 3Q25 commercialization of ZUNVEYL, driven by expansion in the U.S. long-term care channel. Pharmacy orders grew 102% sequentially, prescription volumes hit record monthly highs, and reach extended to >600 nursing homes with a prescriber base above 500 clinicians. Revenue for the quarter was $2.8M, comprising $2.3M of ZUNVEYL net product sales and $0.5M of licensing revenue. Pro forma cash after an October equity raise is about $73.2M, with a $75M ATM facility and roughly two years of runway at planned operating spend. Management continues to prioritize an LTC-focused call strategy to drive durable adoption and repeat ordering.
Alpha Cognition (NASDAQ: ACOG) ha riportato un'accelerazione della commercializzazione di ZUNVEYL nel terzo trimestre 2025, guidata dall'espansione nel canale assistenza a lungo termine degli Stati Uniti. Ordin i in farmacia cresciuti del 102% sequenzialmente, i volumi di prescrizioni hanno raggiunto massimi mensili storici, e la copertura si è estesa a oltre 600 strutture di assistenza con una base di prescrittori superiore a 500 professionisti. Il fatturato del trimestre è stato $2,8M, di cui $2,3M da vendite nette di ZUNVEYL e $0,5M da entrate da licenze. La cassa pro forma dopo una raccolta di capitale di ottobre è di circa $73,2M, con una linea ATM di $75M e circa due anni di runway al tenuto conto della spesa operativa pianificata. La direzione continua a dare priorità a una strategia di contatto incentrata sull'LTC per guidare un'adozione duratura e ordini ripetuti.
Alpha Cognition (NASDAQ: ACOG) reportó una aceleración de la comercialización de ZUNVEYL en el 3Q25, impulsada por la expansión en el canal de cuidados a largo plazo de los Estados Unidos. Los pedidos de farmacia crecieron un 102% secuencialmente, los volúmenes de prescripciones alcanzaron máximos mensuales históricos, y la cobertura se extendió a >600 residencias con una base de prescriptores superior a 500 profesionales. Los ingresos del trimestre fueron $2,8M, compuestos por $2,3M de ventas netas de ZUNVEYL y $0,5M de ingresos por licencias. La caja pro forma tras una ronda de capital en octubre es de aproximadamente $73,2M, con una instalación ATM de $75M y aproximadamente dos años de runway con el gasto operativo planificado. La dirección continúa priorizando una estrategia de llamada centrada en LTC para impulsar una adopción duradera y pedidos repetidos.
알파 코그니션(NASDAQ: ACOG)은 ZUNVEYL의 3Q25 상용화가 가속화되었음을 보고했습니다. 이는 미국의 장기 요양 채널 확장에 의해 촉진되었으며 약국 주문은 전 분기 대비 102% 증가했고 처방전 건수는 월간 기록치를 경신했으며 커버리지는 600곳이 넘는 요양원으로 확장되었고 처방가들은 500명 이상의 임상의 기반을 보유했습니다. 분기 매출은 $2.8M이며 그 중 $2.3M은 ZUNVEYL의 순제품 매출, $0.5M은 라이선스 매출입니다. 10월 주식 발행 후의 프로 포마 현금은 약 $73.2M이고 $75M의 ATM 설비와 계획된 운영 지출로 약 2년의 runway를 가집니다. 경영진은 지속 가능한 도입과 재주문을 이끌기 위해 LTC 중심의 콜 전략을 계속 우선시합니다.
Alpha Cognition (NASDAQ: ACOG) a annoncé une accélération de la commercialisation de ZUNVEYL au troisième trimestre 2025, tirée par l'expansion dans le canal soins de longue durée aux États-Unis. Les commandes en pharmacie ont progressé de 102% séquentiellement, les volumes de prescriptions ont atteint des sommets mensuels historiques, et la couverture s'est étendue à plus de 600 maisons de repos avec une base de prescripteurs supérieure à 500 cliniciens. Le chiffre d'affaires du trimestre s'établit à $2,8M, composé de $2,3M de ventes nettes de ZUNVEYL et $0,5M de revenus de licences. La trésorerie pro forma après une levée d'equity en octobre est d'environ $73,2M, avec une facilitation ATM de $75M et environ deux ans de runway au vu des dépenses d'exploitation prévues. La direction continue de privilégier une stratégie d'appels axée LTC pour favoriser une adoption durable et des commandes répétées.
Alpha Cognition (NASDAQ: ACOG) meldete eine beschleunigte Markteinführung von ZUNVEYL im 3Q25, getrieben durch die Expansion im US-amerikanischen Langzeitpflegekanal. Apothekerbestellungen stiegen um 102% gegenüber dem Vorquartal, Verschreibungsvolumen erreichte monatliche Rekordwerte, und die Reichweite erstreckte sich auf über 600 Pflegeheime mit einer Verschreiberbasis von über 500 Klinikern. Der Umsatz im Quartal betrug $2,8 Mio, bestehend aus $2,3 Mio ZUNVEYL-Nettoverkauf und $0,5 Mio Lizenzumsätzen. Pro-forma-Barbestand nach einer Oktober-Eigenkapitalerhöhung liegt bei ca. $73,2 Mio, mit einer ATM-Fazilität von $75 Mio und grob zwei Jahre Runway basierend auf geplanter operativer Ausgabe. Das Management priorisiert weiterhin eine LTC-fokussierte Call-Strategie, um eine dauerhafte Adoption und wiederkehrende Bestellungen zu fördern.
Alpha Cognition (NASDAQ: ACOG) أبلغت عن تسريع تسويق ZUNVEYL في الربع الثالث 2025، مدفوعاً بالتوسع في قناة الرعاية الطويلة الأجل في الولايات المتحدة. ارتفعت طلبات الصيادلة 102% على التوالي، وبلغت أحجام الوصفات الطبية أرقاماً قياسية شهرية، وتوسعت التغطية إلى أكثر من 600 دار رعاية مع وجود قاعدة من الأطباء أكثر من 500 طبيب. كان الإيراد للربع $2.8M، ويتكون من $2.3M من مبيعات ZUNVEYL الصافية و $0.5M من عوائد الترخيص. النقد وفق نموذج pro forma بعد جمع رأس المال في أكتوبر حوالي $73.2M، مع تسهيل ATM بقيمة $75M وحوالي سنتين من runway أمام الإنفاق التشغيلي المخطط. تواصل الإدارة إعطاء الأولوية لاستراتيجية مكالمات تركز على LTC لتعزيز التبني المستدام وتكرار الطلبات.
- Pharmacy orders +102% sequential growth
- Quarter revenue of $2.8M, including $2.3M net product sales
- Prescriber base exceeded 500 clinicians
- Pro forma cash ~ $73.2M after October equity raise
- Pro forma cash provides roughly two years of runway at planned spend
- Commercial revenue remains modest at $2.8M in 3Q25
Dallas, Texas--(Newsfile Corp. - November 14, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition completed its second quarter of ZUNVEYL® commercialization in 3Q25, with launch momentum accelerating across the U.S. long-term care (LTC) channel. Pharmacy orders grew
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Revenue reached
$2.8M in the quarter, including$2.3M of ZUNVEYL net product sales and$0.5M in licensing revenue with strong sequential growth. - Pro forma cash is about
$73.2M after the October equity raise, providing roughly two years of runway at planned operating spend and supported by a$75M ATM facility. - ZUNVEYL launch momentum is building with more than 500 prescribers, coverage of over 600 nursing homes, and pharmacy orders more than doubling q/q.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274515
FAQ
How much revenue did Alpha Cognition (ACOG) report for 3Q25?
What portion of 3Q25 revenue was ZUNVEYL net product sales for ACOG?
How fast did pharmacy orders for ZUNVEYL grow in 3Q25 for ACOG?
How many prescribers and nursing homes does ACOG report for the ZUNVEYL launch?
What is Alpha Cognition's cash position and runway after the October equity raise?
Does Alpha Cognition have additional financing available beyond cash on hand?
